Peptide evidence preview
Selank: evidence, mechanism, and limitations
A dose-free evidence preview of Selank’s proposed neurobiological mechanisms, limited human studies, uncertainty, and regulatory context.
Direct answer
Direct answer
Selank is a synthetic peptide derived from tuftsin and developed in Russia. Limited human studies report anxiety-related and neuroimaging signals, but the evidence base is small and geographically concentrated; most proposed mechanisms are preclinical. It is not approved by the U.S. Food and Drug Administration or Health Canada.
Public Evidence Passport preview
Limited human signals + mostly preclinical mechanism
Small human studies report signals, but the body of clinical evidence lacks large, independent, multicenter placebo-controlled trials. Most mechanistic claims remain laboratory or animal findings.
- Strongest source tier
- Tier 3 — small comparative or placebo-controlled human study
- Editorial review
- August 4, 2026
- Source coverage
- 4 inspectable records in this public preview
What matters
- Proposed GABAergic, neurotrophic, monoaminergic, and immune mechanisms are mostly preclinical.
- The most cited clinical comparison was small, single-country, and not placebo-controlled.
- An acute neuroimaging study found connectivity changes, not a demonstrated clinical or cognitive benefit.
- Long-term safety and interactions with other central nervous system agents are not adequately characterized.
What Selank is
Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin. It was developed in Russia and is registered there for selected anxiety-related and asthenic conditions. Registration in one jurisdiction does not establish approval or evidence acceptance elsewhere.
Proposed mechanisms
Laboratory and animal studies describe indirect interaction with GABA-related signaling, changes in monoamine metabolism, neurotrophic signaling, enkephalin biology, and immune pathways. One cell study found no direct effect from Selank alone on the measured GABAergic gene-expression markers but reported modulation in the presence of GABA.
These findings help form hypotheses. They do not establish a primary human mechanism or a clinical outcome.
What the human evidence shows
A small Russian comparative study reported anxiety-related benefits versus an active comparator. It was not placebo-controlled and has limited external validity. A separate placebo-controlled acute neuroimaging study in healthy volunteers reported changes in functional connectivity involving the amygdala and temporal regions.
A brain-imaging signal is not the same as improved anxiety, cognition, or daily function. Large independent trials and systematic clinical syntheses are absent.
Safety and uncertainty
Available reports suggest low acute toxicity, but the evidence is limited and does not establish long-term safety. Potential interactions with sedating, GABA-active, serotonergic, opioid, or other psychiatric medicines have not been adequately studied in humans.
Selank is not approved by the U.S. Food and Drug Administration or Health Canada. Questions about an individual’s symptoms, medicines, or suitability require a licensed healthcare provider.
Inspect the record
Sources
- 01Selank in generalized anxiety disorders and neurastheniaPubMed
Small active-comparator study; not placebo-controlled.
- 02GABA, Selank, and gene expression in IMR-32 cellsPubMed
In-vitro mechanistic study.
- 03Functional connectomic approach to studying Selank and SemaxPubMed
Acute neuroimaging signal in healthy participants, not a clinical outcome.
- 04PubMed
Go deeper
Carry the evidence library in your pocket.
Peptidia for iPhone adds the full reviewed library, inspectable study cards, grounded questions, and a private wellness journal—without numeric doses or protocols.